Protagonist Therapeutics Reports Third Quarter 2026 Financial Results

Protagonist Therapeutics reported third-quarter 2026 revenue of $274.4 million, above analyst expectations of $238.5 million. FDA approval of MIMRYLO (rusfertide) for erythrocytosis in adults with polycythemia vera triggered $275 million in payments. The company had $834.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026. Management plans to begin a Phase 2b program for oral IL-17 antagonist PN-881 in psoriasis in early Q1 2027.